Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study

Table 3 Difference between indacaterol and placebo for average and peak QTcF on Days 1 and 14

	Indacaterol 150 μg vs placebo		Indacaterol 300 μg vs placebo		Indacaterol 600 μg vs placebo
	Least squares mean (90% confidence intervals)
	Day 1	Day 14	Day 1	Day 14	Day 1	Day 14
Average QTcF (ms)	0.66	1.32	2.09	1.04	3.71	1.00
	(-0.22, 1.53)	(-0.20, 2.84)	(1.21, 2.96)	(-0.48, 2.56)	(2.64, 4.79)	(-0.85, 2.84)
Peak QTcF (ms)	-0.21	1.23	2.04	0.38	3.57	0.45
	(-1.40, 0.97)	(-0.56, 3.02)	(0.86, 3.22)	(-1.41, 2.17)	(2.12, 5.02)	(-1.72, 2.62)

Analysis of covariance including baseline QTcF as a covariate and treatment as a fixed effect
Average QTcF is the average of all scheduled post dose QTcF measurements between dosing and 24 h post-dose
Peak QTcF is the maximum QTcF of all scheduled post-dose QTcF measurements between dosing and 24 h post-dose

ISSN: 1471-2466